HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid

a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
Also Known As:
PPADS
Networked: 56 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Spyer, K Michael: 4 articles (09/2005 - 04/2002)
2. Illes, P: 3 articles (03/2010 - 05/2006)
3. Gourine, Alexander V: 3 articles (09/2005 - 04/2002)
4. Kim, Yong-Chul: 2 articles (01/2013 - 07/2005)
5. Illes, Peter: 2 articles (01/2013 - 01/2011)
6. Paton, Julian F R: 2 articles (03/2011 - 09/2002)
7. Sperlágh, B: 2 articles (03/2010 - 10/2007)
8. Jacobson, Kenneth A: 2 articles (04/2009 - 07/2005)
9. Gourine, Valery N: 2 articles (09/2005 - 04/2002)
10. Poputnikov, Dmitry M: 2 articles (09/2005 - 04/2002)

Related Diseases

1. Ischemia
01/01/2011 - "The functional recovery monitored by qEEG was improved by PPADS indicated by an accelerated recovery of ischemia-induced qEEG changes in the delta and alpha frequency bands along with a faster and sustained recovery of motor impairments. "
01/01/2011 - "The effects of inhibition of P2 receptors by pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) on electrophysiological, functional and morphological alterations in an ischemia model with permanent middle cerebral artery occlusion (MCAO) were investigated up to day 28. "
12/01/2010 - "Third, pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid, a P2 receptor antagonist, abolished the responses of six afferents to epicardial ATP (2 μmol) and attenuated the ischemia-related increase in activity of seven other afferents by 37%. "
01/01/2014 - "In control conditions, the relaxation to acetylcholine was not altered by PPADS or Reactive Blue 2. The relaxation to acetylcholine was reduced after ischemia-reperfusion, and, in this condition, it was further reduced by treatment with PPADS or Reactive Blue 2. Likewise, the relaxation to acetylcholine was reduced by L-NAME, and reduced further by Reactive Blue 2 but not by PPADS. "
10/12/2007 - "The P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS, 0.1-10 microM), and the selective P2X(7) receptor antagonist Brilliant Blue G (1-100 nM), decreased OGD-evoked [(3)H]glutamate efflux indicating that endogenous ATP facilitates ischemia-evoked glutamate release. "
2. Paresis (Hemiparesis)
3. Migraine Disorders (Migraine)
4. Pain (Aches)
5. Neuralgia (Stump Neuralgia)

Related Drugs and Biologics

1. Sumatriptan (Imigran)
2. Aspirin (Acetylsalicylic Acid)
3. Adenosine Triphosphate (ATP)
4. Suramin (Suramin Sodium)
5. 2',3'-dialdehyde ATP
6. Bee Venoms (Bee Venom)
7. purine
8. coomassie Brilliant Blue
9. Purinergic P2 Receptors (ADP Receptor)
10. Uridine Triphosphate (UTP)

Related Therapies and Procedures

1. Intravitreal Injections
2. Catheters
3. Ligation
4. Spinal Injections
5. Injections